{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003290","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.421845+00:00","generated_at":"2026-05-28T06:23:28.138104+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Precision BioSciences reports $108.5M preliminary cash; receives $2.5M from TG Therapeutics, issues shares","bullets":["Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.","Expects cash runway into second half of 2026, sufficient to fund two wholly owned programs through Phase 1 data readouts.","On Jan 6, 2025, received $2.5M deferred cash payment from TG Subsidiary and issued 220,712 shares of common stock.","The payment and shares relate to the January 2024 License Agreement for non-oncology applications of allogeneic CAR T therapy azer-cel.","These estimates are preliminary and subject to audit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003290","json":"https://secwatch.observer/filing/0000950170-25-003290.json","markdown":"https://secwatch.observer/filing/0000950170-25-003290.md","text":"https://secwatch.observer/filing/0000950170-25-003290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/0000950170-25-003290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/dtil-20250106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:23:28.138104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}